Table 1:
Description of study sample (N=601), current cigarette smokers enrolled in a smoking cessation trial at 3 diverse primary care clinics in San Francisco, CA from 2014 to 2015
| Full sample (N=601) | Cigarette-only smokers (N=292, 48.6%) | Dual-use of cigarettes and e-cigarettes (N=63, 10.5%) | Dual-use of cigarettes and cannabis (N=183, 30.4%) | Poly-use of cigarettes, e-cigarettes, and cannabis (N=63, 10.5%) | Significance (df) | |
|---|---|---|---|---|---|---|
| Age (M, SD) | 50.8 (11.4) | 53.2 (11.2) | 49.4 (10.6) | 49.3 (11.3) | 45.5 (10.8) | F(3, 596)=10.7*** |
| Gender female (%, N) | 38.1% (229) | 45.2% (132) | 36.5% (23) | 30.6% (56) | 28.6% (18) | χ2(3)=13.1** |
| Race/ethnicity (%, N) | χ2(9)=8.5 | |||||
| NH White | 31.5% (189) | 30.8% (90) | 30.2% (19) | 31.2% (57) | 36.5% (23) | |
| NH Black | 36.9% (222) | 36.3% (106) | 36.5% (23) | 41.5% (76) | 27.0% (17) | |
| Hispanic | 17.1% (103) | 18.5% (54) | 14.3% (9) | 13.7% (25) | 23.8% (15) | |
| Other | 13.8% (83) | 13.4% (39) | 19.0% (12) | 13.7% (25) | 11.1% (7) | |
| Education (%, N) | χ2(9)= 22.8** | |||||
| Less than high school degree | 21.1% (127) | 24.0% (70) | 15.9% (10) | 19.1% (35) | 19.0% (12) | |
| High school degree | 26.3% (158) | 23.6% (69) | 23.8% (15) | 31.7% (58) | 25.4% (16) | |
| Some college | 36.9% (222) | 31.8% (93) | 39.7% (25) | 39.9% (73) | 49.2% (31) | |
| College degree | 14.6% (88) | 19.2% (56) | 19.0% (12) | 8.7% (16) | 6.3% (4) | |
| Clinic site (%, N) | χ2(6)= 30.3*** | |||||
| ZSFG – RFPC | 29.3% (176) | 33.2% (97) | 27.0% (17) | 25.1% (46) | 25.4% (16) | |
| ZSFG – PHP | 41.9% (252) | 32.5% (95) | 36.5% (23) | 53.0% (97) | 58.7% (37) | |
| UCSF | 28.8% (173) | 34.2% (100) | 36.5% (23) | 21.9% (40) | 15.9% (10) | |
| Comorbidities1 (%, N) | ||||||
| HIV/AIDS | 26.3% (158) | 19.5% (57) | 23.8% (15) | 36.1% (66) | 31.8% (20) | χ2(3)=25.4*** |
| Cancer | 9.7% (58) | 11.3% (33) | 6.4% (4) | 9.8% (18) | 4.8% (3) | χ2(3)=2.8 |
| Mental disorder2 | 39.1% (235) | 38.0% (111) | 38.1% (24) | 39.3% (72) | 44.4% (28) | χ2(3)=4.8 |
| Alcohol dependence | 10.7% (64) | 11.6% (34) | 11.1% (7) | 8.7% (16) | 11.1% (7) | χ2(3)=1.3 |
| Drug dependence | 23.8% (143) | 19.9% (58) | 22.2% (14) | 28.4% (52) | 30.2% (19) | Χ2(3)=9.5* |
| Cerebrovascular disease | 7.8% (47) | 7.5% (22) | 7.9% (5) | 7.7% (14) | 9.5% (6) | χ2(3)=0.7 |
| Pulmonary disease | 25.5% (153) | 23.3% (68) | 30.2% (19) | 29.0% (53) | 20.6% (13) | χ2(3)=3.8 |
| Cardiovascular disease | 33.6% (202) | 36.0% (105) | 36.5% (23) | 32.8% (60) | 22.2% (14) | χ2(3)=6.0 |
Note:
comorbidity data from medical records was missing for N=230 participants on all measures except for HIV/AIDS and cardiovascular disease (N missing = 310)
includes schizophrenic disorders, episodic mood disorders, anxiety, dissociative and somatoform disorders, posttraumatic stress disorder, and depressive disorder, not elsewhere classified
df = degrees of freedom; NH = Non-Hispanic; ZSFG – RFPC = Zuckerberg San Francisco General Hospital Richard H. Fine People’s Clinic, ZSFG – PHP = UCSF Positive Health Clinic at Zuckerberg San Francisco General Hospital; UCSF = University of California San Francisco General Internal Medicine Clinic;
p<.05;
p<.01;
p<.001.